In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes

Diabetes Technology and Therapeutics

Volumn 15, Issue 10, 2013, Pages 802-809

  Micheletto, Francesco ^a   Dalla Man, Chiara ^a   Kolterman, Orville ^b   Chiquette, Elaine ^b   Herrmann, Kathrin ^b   Schirra, Jörg ^c   Kovatchev, Boris ^d   Cobelli, Claudio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PLACEBO; PRAMLINTIDE;

ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STOMACH EMPTYING;

BLOOD GLUCOSE; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC EMPTYING; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; ISLET AMYLOID POLYPEPTIDE; MALE; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884538970     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0054     Document Type: Article

References (35)

1. Van De Waterbeemd H, Gifford E: ADMET in silico modelling: towards prediction paradise Nat Rev Drug Discov 2003;2:192-204. (Pubitemid 37361664)
2. Kapetanovic IM: Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact 2008;171:165-176. (Pubitemid 351146652)
3. Cobelli C, Dalla Man C, Sparacino G, Magni L, Nicolao G, Kovatchev BP: Diabetes: models, signals, and control. IEEE Rev Biomed Eng 2009;2:54-96.
4. Eddy DM, Schlessinger L: Archimedes: a trial-validate model of diabetes. Diabetes Care 2003;26:3093-3101.
5. Eddy DM, Schlessinger L: Validation of the Archimedes diabetes model. Diabetes Care 2003;26:3102-3110. (Pubitemid 37339505)
6. Widmark EMP: Die Theoretischen Grundlagen und die Praktische Verwendbarkeit der Gerichtlich-Medizinischen Alkoholbestimmung. Berlin: Urban & Schwarzenberg, 1932.
7. Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236: E667-E677. (Pubitemid 9220487)
8. Dalla Man C, Rizza RA, Cobelli C: Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng 2007;54: 1740-1749. (Pubitemid 47450539)
9. Dalla Man C, Raimondo DM, Rizza RA, Cobelli C: GIM, simulation software of meal glucose-insulin model. J Diabetes Sci Technol 2007;1:323-330.
10. Kovatchev BP, Breton M, Man CD, Cobelli C: In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 2009;3:44-55.
11. Cobelli C, Renard E, Kovatchev BP: Perspectives in diabetes: artificial pancreas: past, present, future. Diabetes 2011;60: 2672-2682.
12. Kovatchev BP, Breton MD, Dalla Man C, Cobelli C: In Silico Model and Computer Simulation Environment Approximating the Human Glucose/Insulin Utilization. Food and Drug Administration Master File MAF 1521. Rockville, MD: Food and Drug Administration, 2008.
13. Pullman J, Darsow T, Frias JP: Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag 2006;2:203-220.
14. Kruger DF, Gatcomb PM, Owen SK: Clinical implications of amylin and amylin deficiency. Diabetes Educ 1999;25: 389-397.
15. Vella A, Lee JS, Camilleri M, Szarka LA, Burton DD, Zinsmeister AR, Rizza RA, Klein PD: Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 2002;14:123-131. (Pubitemid 34451212)
16. Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG: The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002;51:636-641. (Pubitemid 34516520)
17. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR: Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003;26:1-8. (Pubitemid 36928987)
18. Weyer C, Gottlieb A, Kim D, Lutz K, Swartz S, Gutierrez M, Wang Y, Ruggles J, Kolterman O, Maggs D: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes. Diabetes Care 2003;26:3074-3079. (Pubitemid 37339501)
19. Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, Wang Y, Burns C, Lush C, Weyer C, Horowitz M: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005;48:838-848. (Pubitemid 40767975)
20. Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG: The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002;51: 636-641. (Pubitemid 34516520)
21. Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O: A double-blind, placebocontrolled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189-2195. (Pubitemid 44899850)
22. Karl D, Philis-Tsimikas A, Darsow T, Lorenzi G, Kellmeyer T, Lutz K, Wang Y, Frias JP: Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther 2007;9:191-199. (Pubitemid 46652555)
23. Huffman DM, McLean GW, Seagrove MA: Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. Endocr Pract 2009;15:689-695.
24. Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW: Twenty-four-hour simultaneous subcutaneous basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. J Clin Endocrinol Metab 2009;94:1608-1611.
25. Schorr AB, Ofan R: Simultaneous use of two external subcutaneous pumps delivering insulin and SYMLIN: use of a double-pump system. J Diabetes Sci Technol 2012;6:1507-1508.
26. Woerle HJ, Albrecht M, Linke R, Zschau S, Neumann C, Nicolaus M, Gerich J, Goke B, Schirra J: Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am J Physiol Endocrinol Metab 2008;294:E103-E109.
27. Woerle HJ, Albrecht M, Linke R, Zschau S, Neumann C, Nicolaus M, Gerich JE, Göke B, Schirra J: Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide. Diabetes Care 2008;31:2325-2331.
28. Magni L, Raimondo DM, Man CD, Breton M, Patek S, Nicolao GD, Cobelli C, Kovatchev BP: Evaluating the efficacy of closed-loop glucose regulation via control-variability grid analysis. J Diabetes Sci Technol 2008;2:630-635.
29. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ: Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience. Arch Intern Med 2009;27:1307-1316.
30. Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjörnsdó ttir S, Eliasson B; Steering Committee of the Swedish National Diabetes Register: Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 2007;30:496-502. (Pubitemid 46354324)
31. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320.
32. JDRF CGM Study Group: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-1476.
33. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, Dubose SN, Hall CA; T1D Exchange Clinic Network: The T1D Exchange Clinic Registry. J Clin Endocrinol Metab 2012;97:4383-4389.
34. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
35. Kong MF, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, Perkins AC, Tattersall RB: The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998;41:577-583. (Pubitemid 28206829)